A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH-Reference-Cited by-同舟云学术

A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH

Published:2023-08-29 Issue:9 Volume:11 Page:
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clinical Case Reports

Author:

Mohamed Sarah¹,Reda Mostafa Mostafa²,Magdi Eid Mohamed²,AbdelQadir Yossef Hassan³,Abdelghafar Yomna Ali³,Swed Sarya⁴^ORCID,Jahshan Bishara²,El‐Radi Waddah Abd²

Affiliation:

1. School of Medicine Cairo University Giza Egypt

2. Department of Medicine Rochester Regional/Unity Hospital Rochester New York USA

3. Faculty of Medicine Alexandria University Alexandria Egypt

4. Faculty of Medicine Aleppo University Aleppo Syria

Abstract

Key Clinical MessageNirmatrelvir‐ritonavir (Paxlovid) is a brand‐new oral antiviral medication for treating mild to severe COVID‐19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir‐nirmatrelvir on December 22, 2021, to treat COVID‐19. We describe a case of mild COVID‐19 infection who developed severe hyponatremia following the administration of Paxlovid. Clinical and laboratory evaluations suggest SIADH, likely secondary to Paxlovid. The potential side effects of this medication still require further study.

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.7860

Reference17 articles.

1. Epidemiology of Hyponatremia

2. Incidence and Prevalence of Hyponatremia

3. Age and gender as risk factors for hyponatremia and hypernatremia

4. Hyponatremia in a Nursing Home Population

5. Mild Chronic Hyponatremia Is Associated With Falls, Unsteadiness, and Attention Deficits

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Severe Metabolic Derangements in a Patient with Hypertension and COVID-19;The Journal of Applied Laboratory Medicine;2024-06-13

2. Esomeprazole/nirmatrelvir+ritonavir/tozinameran;Reactions Weekly;2023-09-30